Physician profile
Ravy S Sun
NPI 1083378996
$5,359.13
in general payments reported to CMS, 2019-2025
17 companies · $2,930 in 2025
The $2,930 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $456 · 2024: $1,973 · 2025: $2,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,359.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,091.18 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $846.35 | 2023-2025 | Otezla, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $613.17 | 2023-2025 | |
| Gilead Sciences, INC. | $583.99 | 2023-2025 | Vemlidy, Epclusa, Biktarvy |
| Novo Nordisk INC | $395.60 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $371.42 | 2024-2025 | Jardiance |
| Abbvie INC. | $367.49 | 2025 | |
| Glaxosmithkline, LLC. | $288.20 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Corcept Therapeutics | $184.04 | 2025 | Korlym |
| Lilly USA, LLC | $161.66 | 2024-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $144.58 | 2023-2025 | Capvaxive, Dificid, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $137.86 | 2025 | Zoryve |
| Renalytix Ai, INC. | $77.59 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Exact Sciences Corporation | $29.86 | 2025 | Cologuard Collection Kit |
| Pfizer INC. | $27.58 | 2023-2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $22.24 | 2024 | Inspire |
| Abbott Laboratories | $16.32 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravy Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.